Literature DB >> 18778756

The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer.

Jaime Acquaviva1, Ricky Wong, Al Charest.   

Abstract

The proto-oncogene receptor tyrosine kinase ROS was originally discovered through the identification of oncogenic variants isolated from tumors. These discoveries spearheaded a body of work aimed at elucidating the function of this evolutionarily conserved receptor in development and cancer. Through genetic and biochemical approaches, progress in the characterization of ROS points to distinctive roles in the program of epithelial cell differentiation during the development of a variety of organs. Although substantial, these advances remain hampered by the absence of an identified ligand, making ROS one of the last two remaining orphan receptor tyrosine kinases. Recent studies on the oncogenic activation of ROS as a result of different chromosomal rearrangements found in brain and lung cancers have shed light on the molecular mechanisms underlying ROS transforming activities. ROS and its oncogenic variants therefore constitute clinically relevant targets for cancer therapeutic intervention. This review highlights the various roles that this receptor plays in multiple system networks in normalcy and disease and points to future directions towards the elucidation of ROS function in the context of ligand identification, signaling pathways and clinical applications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18778756     DOI: 10.1016/j.bbcan.2008.07.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  64 in total

Review 1.  Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies.

Authors:  Priscilla K Brastianos; Franziska Maria Ippen; Umbreen Hafeez; Hui K Gan
Journal:  Oncologist       Date:  2018-04-27

2.  Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Sai-Hong I Ou; Yung-Jue Bang; D Ross Camidge; Benjamin J Solomon; Ravi Salgia; Gregory J Riely; Marileila Varella-Garcia; Geoffrey I Shapiro; Daniel B Costa; Robert C Doebele; Long Phi Le; Zongli Zheng; Weiwei Tan; Patricia Stephenson; S Martin Shreeve; Lesley M Tye; James G Christensen; Keith D Wilner; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2014-09-27       Impact factor: 91.245

Review 3.  Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer.

Authors:  Mukesh Kumar; Vinicius Ernani; Taofeek K Owonikoko
Journal:  Mol Aspects Med       Date:  2015-07-14

Review 4.  Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.

Authors:  Eamon M Berge; Robert C Doebele
Journal:  Semin Oncol       Date:  2013-12-12       Impact factor: 4.929

5.  Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.

Authors:  Jieyu Wu; Yunen Lin; Xinming He; Haihong Yang; Ping He; Xinge Fu; Guangqiu Li; Xia Gu
Journal:  BMC Cancer       Date:  2016-08-04       Impact factor: 4.430

6.  Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology.

Authors:  Lester J Layfield; Sinchita Roy-Chowdhuri; Zubair Baloch; Hormoz Ehya; Kim Geisinger; Susan J Hsiao; Oscar Lin; Neal I Lindeman; Michael Roh; Fernando Schmitt; Nikoletta Sidiropoulos; Paul A VanderLaan
Journal:  Diagn Cytopathol       Date:  2016-08-26       Impact factor: 1.582

Review 7.  Molecular pathways: ROS1 fusion proteins in cancer.

Authors:  Kurtis D Davies; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2013-05-29       Impact factor: 12.531

Review 8.  Immunohistochemistry for predictive biomarkers in non-small cell lung cancer.

Authors:  Mari Mino-Kenudson
Journal:  Transl Lung Cancer Res       Date:  2017-10

Review 9.  New targets in non-small cell lung cancer.

Authors:  Shirish M Gadgeel
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

10.  Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

Authors:  Kurtis D Davies; Anh T Le; Mariana F Theodoro; Margaret C Skokan; Dara L Aisner; Eamon M Berge; Luigi M Terracciano; Federico Cappuzzo; Matteo Incarbone; Massimo Roncalli; Marco Alloisio; Armando Santoro; D Ross Camidge; Marileila Varella-Garcia; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2012-08-23       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.